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Abstract  
Aims─ Heart failure (HF) has become an epidemic and constitutes a major medical,  
social and economic problem worldwide. Despite advances in medical treatment, HF  
prognosis remains poor. The development of efficient therapies is hampered by the lack  
of appropriate animal models in which HF can be reliably determined, particularly in  
mice. The development of HF in mice is often assumed based on the presence of cardiac  
dysfunction, but HF itself is seldom proved. Lung ultrasound (LUS) has become a helpful  
tool for lung congestion assessment in patients at all stages of HF. We aimed to apply this  
non-invasive imaging tool to evaluate HF in mouse models of both systolic and diastolic  
dysfunction.   
Methods and results─ We used LUS to study HF in a mouse model of systolic  
dysfunction, dilated cardiomyopathy, and in a mouse model of diastolic dysfunction,  
diabetic cardiomyopathy. LUS proved to be a reliable and reproducible tool to detect  
pulmonary congestion in mice. The combination of LUS and echocardiography allowed  
discriminating those mice that develop HF from those that do not, even in the presence  
of evident cardiac dysfunction.  The study showed that LUS can be used to identify the  
onset of HF decompensation and to evaluate the efficacy of therapies for this syndrome.  
Conclusions─ This novel approach in mouse models of cardiac disease enables for the  
first time to adequately diagnose HF non-invasively in mice with preserved or reduced  
ejection fraction, and will pave the way to a better understanding of HF and to the  
development of new therapeutic approaches.  
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Introduction  
Heart failure (HF) represents a global pandemic with an increasing prevalence and is a  
major cause of death and hospitalisation worldwide.1,2 HF is a complex clinical syndrome  
characterized by typical symptoms, such as dyspnoea, shortness of breath and fatigue,  
and typical clinical signs as congestion, pleural effusion and/or oedema.3 HF is caused by  
structural and/or functional abnormalities that lead to systolic or diastolic dysfunction,  
resulting in inefficient cardiac contraction (HF with reduced ejection fraction, HFrEF) or  
inefficient relaxation (HF with preserved ejection fraction, HFpEF), respectively.  
However, cardiac dysfunction itself is not an evidence of HF.3 Despite advances in the  
treatment of HF during the last decades, the prognosis for these patients remains poor. In  
order to identify appropriate therapies appropriate preclinical testing in animal models is  
needed.4   
HF is diagnosed in humans mainly based on symptoms and clinical signs.3 However, in  
mice, which are the most widely used animal model in research, it is very difficult to  
evaluate symptoms as dyspnoea, shortness of breath and fatigue, and traditionally  
researchers have assumed the presence of HF based merely on cardiac dysfunction, which  
does not necessarily lead to HF. The diagnosis of HF requires the presence of reduced  
LVEF (in HFrEF) or preserved LVEF with clear evidence of diastolic dysfunction (in  
HFpEF), but also findings commonly associated with HF itself in humans, such as  
pulmonary congestion. Cardiac dysfunction may or may not lead to HF, and therefore the  
detection of this condition is not an appropriate substitute for the assessment of HF. The  
lack of proper analytical methods to assess the development of HF in mice is hampering  
efficient preclinical studies in mice that would allow the development of new therapies  
for HF that are urgently needed.5 This limitation is particularly relevant in mouse models  
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of diastolic dysfunction, commonly described as HFpEF, syndrome which has increasing  
prevalence, poor prognosis and for which treatment is not available.6,7   
A universal mechanism leading to symptoms in HF is pulmonary congestion, which is  
defined by accumulation of extravascular lung water that precludes efficient gas transport  
in the alveoli and eventually results in dyspnoea and fatigue. Lung ultrasound (LUS) has  
emerged in medicine as a readily available, highly reproducible and efficient method for  
the assessment of pulmonary congestion.8–12 LUS is especially useful to determine  
pulmonary oedema and pleural effusion, which are common manifestations of HF.9,11,13  
However, to our knowledge LUS has not been used to detect HF in mouse models of  
cardiac disease. Here we provide for first time a translational non-invasive method based  
on combined echocardiography and LUS that enables researchers to study HF progression  
in mouse models of systolic and diastolic dysfunction and to evaluate the efficacy of  
treatments for this syndrome.  
  
Methods  
Additional information on the methods is provided in the online supplement. The studies  
were performed conform the Guide for the care and use of laboratory animals. All animal  
procedures were approved by the appropriate local and regional ethical committees for  
animal experimentation.  
 Mouse models of systolic and diastolic dysfunction  
Mice  
Male mice housed in an air conditioned room with a 12 h light/dark cycle and free access  
to water and chow were used in this study.   
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Dilated cardiomyopathy  
Yme1lLoxP/LoxP mice were crossed to mice expressing the Cre recombinase specifically in  
cardiomyocytes (Myh6-Cre; cYKO). These mice develop dilated cardiomyopathy  
(DCM) by 40 weeks of age and have been previously described.14 A total of 35 wild type  
(WT) and 34 Yme1lLoxP/LoxP mice (Ctl group and DCM group, respectively) were included  
for cardiac and pulmonary echography examination at 8 (Ctl, n=8; DCM, n=8), 16 (Ctl,  
n=9; DCM, n=8), 28 (Ctl, n=9; DCM, n=9) and 40 weeks (Ctl, n=9; DCM, n=9). Mice  
were euthanized individually using a CO2-filled chamber, at 28 and 40 weeks, to obtain  
lungs and hearts.   
Diabetic cardiomyopathy  
A murine type 1 diabetes model was used to study HFpEF. Twenty-one mice, 16-20  
weeks old, weight 25-30 g were used. Diabetes was induced by injecting streptozotocin  
(STZ, 50 mg/kg, 0.05 mol/L in citrate buffer, pH 4.5, Sigma, St. Louis, USA) i.p for five  
consecutive days (Diabetic group, n=14). The remaining mice (n=7) received the same  
volume of saline solution i.p. during the same number of days and were used as controls.  
Blood glucose (BG) levels were monitored in all mice before STZ injection and every 4  
weeks during 28 weeks to confirm the induction of diabetes. Samples for BG analysis  
were taken from the tail vein following 4 hours of starvation and measured using a glucose  
oxidase test trip (FreeStyle, Abbott Diabetes Care Inc., USA). Cardiac and pulmonary  
ultrasound was performed before STZ injection (baseline) and 4, 8, 12, 16, 20, 24 and 28  
weeks post-diabetes induction. Those diabetic mice with the highest lung ultrasound score  
(see below) were injected with the diuretic drug furosemide (10 mg/Kg, s.c. injection,  
twice per day during 7 days). Afterwards, mice were euthanatized individually using a  
CO2-filled chamber, and the lungs and the heart were isolated.  
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Cardiac and pulmonary echography protocol  
Transthoracic echocardiography examination was blinded performed by an expert  
operator using a high-frequency ultrasound system (Vevo 2100, Visualsonics Inc.,  
Canada) with a 30-MHz linear probe. Two-dimensional (2D) and M-mode (MM)  
echography were performed at a frame rate above 230 frames/sec, and pulse wave  
Doppler (PW) was acquired with a pulse repetition frequency of 40 kHz. Mice were  
lightly anesthetized with 0.5-2% isoflurane in oxygen, administered via nose cone and  
adjusting the isoflurane delivery trying to maintain the HR in 450±50 bpm. Mice were  
placed in supine position using a heating platform and warmed ultrasound gel was used  
to maintain normothermia. A base apex electrocardiogram (ECG) was continuously  
monitored through 4 leads placed on the platform and connected to the ultrasound  
machine. Images were transferred to a computer and were analysed off-line by a blinded  
expert using the Vevo 2100 Workstation software.  
Echocardiography  
For LV systolic function assessment, parasternal standard 2D long and short axis views  
(LAX and SAX view, respectively) were acquired.15 LV ejection fraction (LVEF) and  
LV end-systolic volume (LVVol;s) were obtained from the LAX view, and LV fractional  
area change (LVFAC) from the SAX view. Right ventricle (RV) systolic function was  
indirectly estimated using the tricuspid annular plane systolic excursion (TAPSE),  
obtained from a 2D 4-chamber apical view, measuring maximum lateral tricuspidal  
annulus movement as previously described for mice.16,17 For the study of diastolic  
dysfunction in the diabetic cardiomyopathy model, mitral valve flow was evaluated using  
pulsed-wave (PW) Doppler echography in the 4-chamber apical view as described.18  
Assessed parameters included early and late diastolic velocity peak wave (E and A,  
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respectively), the E/A ratio and isovolumetric relaxation time (IVRT).15 According to the  
E/A ratio observed, mitral flow was classified in 2 categories: normal pattern, defined  
according to data observed in Ctl group (E/A ratio ranged between 1.35 and 4.00), and  
abnormal pattern (E/A ration <1.35 and >4.00). Furthermore, LV diastolic end-diastolic  
volume , left atrial end-systolic internal diameter in 2D LAX, and pulmonary artery (PA)  
flow, just at the beginning of the PA, from a modified angled 2D LAX view, were also  
examined to identify the presence of left side cardiac congestion as well as pulmonary  
hypertension.19 PW Doppler was displayed just at the beginning of the PA. The PA  
acceleration time (PA accT), PA mean velocity (PA Mean Vel) and PA velocity time  
integral (PA VTI) were measured.  
Lung ultrasound  
Left and right side pulmonary fields were longitudinally scanned to visualize the pleural  
line, pleural space and lung layers (video 1). The pattern observed was classified  
according to the lung sliding during respiration, predominant lines profile, echography  
bedside colour, as well as the presence or absence of Z lines, pleural thickness, pleural  
defects and pleural effusion, similarly to previous reports in human medicine 11,13,20 (Fig.  
1 and 2). The different parameters were defined and classified as follows:  
Lung sliding: refers to the horizontal movement of the pleural, coinciding with  
respirations. Normal sliding is considered when clear movement is detected; low  
sliding when poor horizontal movement is detected; absent sliding is determined  
when the pleura does not show horizontal motion with respiration. Consider that  
a non-horizontal abrupt movement could be seen as a result of cardiac contraction  
or abdominal reinforcement for breathing. Lung sliding must be evaluated in live  
images that allow motion to be observed (i.e. not still).      
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Line profile: given by the characteristics of the lines produced by the air artefact.  
A lines are defined as horizontal hyperechoic lines and horizontal repetitions  
artefacts visible below the pleural line, indicating air (Fig. 1A). B lines are defined  
as hyperechoic, long, well-defined and laser-like comet-tail artefacts arising from  
the pleural line and erasing A-lines, and may indicate interstitial syndrome or  
oedema (Fig. 1B). According to the kind of lines observed in the LUS, the line  
profile was classified as A, AB or B (Fig. 2A). An A profile was assigned when  
only A lines are visualized and no B lines are detected; AB profile was defined as  
a mixed pattern, with visible A lines and clear B lines identified (Fig. 2A), whereas  
a B profile was scored when broad B lines were visualized and no normal A lines  
were identified.   
Colour profile: determined by the predominant colour observed in the background  
lung pattern. Black colour indicates a normal lung, which full of air produces an  
echography background pattern that is black (white colour is visualized only in  
the A lines themselves). White colour indicates severe interstitial oedema/alveolar  
oedema and is caused by high water content and no air in the lung, which produces  
a white echography background pattern. For classification, black colour was  
selected when no white areas (except for the A lines themselves) are seen. Black  
and white colour, which indicates mild/moderate interstitial oedema, was selected  
when white areas were observed but a black background was still present, giving  
an appearance of a mixed pattern and indicating less air content than normal in  
lungs and some fluid accumulation (Fig. 2B). White colour was selected when the  
entire lung appears with a white colour, with no evidence of normal pattern  
behind.    
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Z lines: these lines refer to small and short hyperechoic, laser-like comet-tail  
artefacts arising from the pleural line that do not reach the edge of the lung field  
(Fig. 1C and 2C). Z lines were considered absent if no Z lines were observed in  
the pleural line. If any Z lines were observed, regardless of the number, these were  
interpreted as present. Z lines are better visualized in live images as they could  
appear and disappear depending on the ultrasound angle.   
Pleural thickness: normal pleural appearance should be smooth and fine. Pleural  
thickening was defined as a marked pleural line widening (> 0.3 mm for mice;  
Fig. 2D) indicating increased pressure in the pleural space.   
Pleural defects: described as an irregular pleural contour with or without  
involvement of the subpleural interstitial area. Pleural defects mostly provide a  
blurred echography and a serrated margin appearance (Fig. 2E).  
Pleural effusion: as physiologic pleural fluid is not usually observed by  
conventional LUS, fluid leaking into the pleural space is considered an abnormal  
finding. Effusion was visualized as an anechoic area between the lung and the  
intercostal space and, most of the times, placed close to the liver. When a small  
but evident amount of free fluid was observed, it was classified as moderate  
effusion. When the effusion was substantial and collapsed the associated  
structures like the lung parenchyma, it was classified as severe (Fig. 2F).    
Lung ultrasound score   
A lung ultrasound score (MoLUS score, for Mouse Lung UltraSound score) was  
developed based on the LUS findings that determine the presence of HF in mice.  
Individual scores were assigned to each parameter as detailed in Table 1, based on their  
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association with the severity of the disease. The MoLUS score represents the sum of the  
individual scores for each parameter.   
To assess the intra-observer and inter-observer agreement in scoring the pulmonary  
echography images, a total of 32 lung images representing various degrees of disease  
severity were scored by 6 blinded evaluators after they were given access to Fig. 2 and  
video S1. These 6 individuals had varying degrees of experience with mouse echography,  
ranging from expert in LU to occasional user of echocardiography. For the assessment of  
inter-observer variation, the intraclass correlation coefficient (ICC) for single measures  
was calculated using the Two-Way Mixed model (ICC3, absolute agreement) with a  
confidence interval of 95% using SPSS. For the assessment of intra-observer variability,  
evaluators were given access to the same images on a separate day after randomization,  
without being told they were the same images. The ICC for the two sets of scores was  
calculated for each evaluator separately using the Two-Way Mixed model (ICC3,  
absolute agreement) and the average of all evaluators was then determined.  
To determine the reliability of the MoLUS score, we studied the relationship of the  
MoLUS score with the lung water content and with echocardiographic parameters related  
to cardiac overload and dysfunction. The correlation of PA AccT with the lung water  
content was also calculated to identify a cut-off value for water content beyond which  
mice would be considered to have lung congestion. Based on the change in the trend of  
the correlation between both parameters, 130 g of water content was chosen as the cut- 
off value. This value was used to stablish an ideal cut-off for the MoLUS score to identify  
mice with clear HF using a receiver-operator characteristic (ROC) curve.  
Statistical analysis  
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Statistical analyses were performed with GraphPad Prism 5.0 (GraphPad software, Inc.,  
www.graphpad.com). Continuous data was expressed as mean ±SD. Comparisons  
between groups of discrete variables were performed using the Chi-squared test and  
continuous variables were tested with an unpaired or paired Student t-test, or a two-way  
analysis of variance (ANOVA) followed by Bonferroni test for multiple comparisons, as  
appropriate. Pearson correlations were used to determine the relationship between the  
different parameters. A receiver-operator characteristic (ROC) curve was used to  
determine the ideal cut-off for the MoLUS score to identify HF. Differences were  
considered statically significant at p<0.05. The ICC for inter- and intra-observer variation  
in the MoLUS was calculated as explained above.  
  
Results  
LUS allows non-invasive assessment of pulmonary congestion associated with HF  
We used high resolution LUS to determine whether those parameters used in humans to  
detect fluid accumulation in the lungs, which are often associated with HF, could be  
observed in mice with heart disease. These include A, B, and Z lines, (Fig. 1A-1C), the  
echography background colour, pleural sliding, pleural thickness, pleural defects and  
pleural effusion (Fig. 2A-2F). As shown in Fig. 1 and Fig. 2, and in more specific  
examples below, the same parameters used in human LUS can be evaluated in mice with  
chronic heart disease and applied to assess the progression of HF. The time required to  
acquire images was about 1 minute for both lungs, representing virtually no increase over  
the time needed for echocardiography.   
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To quantify the different parameters associated with HF, we developed a simple score  
that assigns numerical values to the different LUS profiles (Table 1, Fig S1). The MoLUS  
score was validated by 6 blinded evaluators with varying degrees of expertise in non- 
invasive imaging (Table S1). The intraclass correlation coefficient (ICC) for single  
measures was 0.817 (CI 0.719-0.894), indicating that all evaluators were assigning very  
similar scores to the different parameters. All evaluators were asked to score the same  
images on a second day. The average of the intra-rater ICC for all evaluators was 0.930,  
confirming the high consistency of the scoring system.  
  
Non-invasive assessment of HFrEF in a mouse model of DCM using LUS  
To investigate the usefulness of LUS to study the development of HF in mice, we first  
used a murine model of dilated cardiomyopathy previously reported in which the Yme1l  
gene is specifically knocked out in cardiomyocytes.14 These mice develop cardiac systolic  
dysfunction and chamber dilatation as a result of mitochondrial fragmentation, and have  
a median life span of 46 weeks.   
We performed cardiac and pulmonary echography in wild-type (Ctl group) and knockout  
(DCM group) mice at 8, 16, 28 and 40 weeks of age. We observed a progressive loss of  
LV contractility in the DCM mice leading to LV systolic dysfunction, which was evident  
at 28 weeks of age (Ctl, 56±8%; DCM, 43±10%; p<0.05) and severe at 40 weeks of age  
(Ctl, 60±9%; DCM, 18±12%; p<0.001; Fig. 3A, Table S2). Following the onset of  
systolic dysfunction, DCM mice developed LV and left atrial volume overload,  
pulmonary flow alterations and impaired RV systolic function observed as a reduction in  
the tricuspid annular plane systolic excursion (TAPSE; Fig. 3B, Table S2, S3). In  
agreement with these results, blood serum analysis and histological evaluation showed an  
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increase in serum BNP, myocardial BNP mRNA expression and diffuse myocardial  
fibrosis in the DCM mice at 40 weeks (Fig. 3C-3E). LUS analysis revealed lung  
congestion features, including cardiogenic oedema and pleural effusion, in the DCM  
group at 40 weeks, which resulted in an increased MoLUS score (Ctl, 0.78±1.09; DCM,  
9.00±7.25; p<0.001; Fig. 4A, 4B, Table S3). In agreement with the higher MoLUS score,  
DCM mice showed a significant increase in lung water content at 40 weeks (Ctl, 103±14  
mg; DCM, 146±28 mg; p<0.01, Fig. 4C). These results provide evidence of how LUS in  
mice helps to distinguish the presence of HF from mere systolic dysfunction.   
Histological lung samples obtained from 40 weeks old mice revealed a slight increase in  
lung perivascular fibrosis with no remarkable changes in macrophage infiltration in DCM  
mice, which was confirmed by qRT-PCR, suggesting mild lung remodelling without  
active inflammation (Fig. S2A-D). These results indicate that the changes in the MoLUS  
score were not the result of lung inflammation.  
  
MoLUS score correlation with lung congestion parameters and determination of the  
cut-off value  
The MoLUS score showed good correlation with the lung water content (r=0.776,  
p<0.001, Fig. 5A), suggesting that it is a reliable tool for non-invasive assessment of  
pulmonary congestion in mice. Furthermore, the MoLUS score showed a significant  
correlation with echocardiographic parameters associated with lung congestion, such as  
PA AccT and left atrium internal diameter (PA AccT, r=0.539, p<0.01, Fig. 5B; LAID,  
r=0.715, <0.001, Fig. 5C), and with parameters of ventricular dysfunction, such as LV  
end diastolic volume and ejection fraction (LVVol,d, r=0.762, p<0.001, Fig 5D; LVEF,  
r=0.819, p<0.001; Fig. 5E).  
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To establish the usefulness of the MoLUS score in identifying mice with HF non- 
invasively, we used a receiver-operator characteristic (ROC) curve analysis in which mice  
were categorized according to their lung water content. Since this is a continuous  
parameter, we first dichotomised the water content values according to their correlation  
with the PA AccT, which has been shown to be a strong indicative of lung congestion.21  
Figure 5F shows a change in the trend of the association between both parameters around  
130 mg of lung water content. Sensitivity analyses showed that this value offered the  
lowest p-value (p=0.042), compared to the median (p=0.184), the mean (p=0.058) or the  
third quartile (p=0.143) cut-offs. The ROC curve analysis of the MoLUS score showed  
an area under the curve of 0.868 (p=0.013, 95% CI 0.6244 to 1.112). The best accuracy  
at detecting higher water content was obtained with MoLUS≥10.5 (sensitivity=83%,  
specificity=100%). We then carried out different sensitivity analyses changing the water  
content cut-off value around 130 mg and both the MoLUS cut-off and its 95% CI (8.3- 
12.7) remained unaltered. Classification of 40-week-old mice according to their MoLUS,  
showed strong significant differences in parameters associated with lung congestion and  
cardiac dysfunction between mice having a MoLUS≥10.5 and those with a lower score  
(Table 2).   
Together, these results demonstrate that LUS is a useful non-invasive imaging method to  
determine and monitor the development of HF in mice with cardiac disease.   
  
Assessment of HFpEF in mice with diastolic dysfunction using LUS   
To determine whether LUS can be applied used to determine the development of HFpEF,  
we used a mouse model of diabetic cardiomyopathy that is known to develop diastolic  
dysfunction.22 As expected, diabetic mice developed hyperglycaemia (Fig. 6A) and both  
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experimental groups showed preserved LV and RV systolic function, with LVEF  
maintained above 50% and with no changes in TAPSE throughout the experimental  
protocol (Fig. 6B; Table S4). A systematic analysis of different diastolic parameters  
showed a significant increase in the number of mice with altered E/A ratio and a  
prolonged isovolumetric relaxation time (IVRT) in the diabetic group, supporting the  
presence of diastolic dysfunction and pointing towards an increase in LV stiffness (Fig.  
6C, Table S5). Diastolic dysfunction was accompanied by increased circulating BNP,  
increased expression of BNP mRNA in the RV and interstitial myocardial fibrosis (Fig.  
6D-F). Diabetic mice also showed a decrease in PA AccT, suggesting that mice develop  
pulmonary remodelling as a consequence of diabetic cardiomyopathy like human patients  
do (Table S6).23 This was further supported by an increase in perivascular collagen  
deposition and lysyl oxidase mRNA expression 28 weeks after STZ injection (Fig. S3A,  
C). Low macrophage infiltration and no change in the leukocyte marker CD45 indicated  
the absence of lung infection in control and diabetic mice (Fig. S3B, D).  
Diabetic mice developed LUS changes associated with lung congestion and progressively  
increased the MoLUS score starting at 12 weeks post-injection, with differences with  
control mice becoming significant at 20 weeks and maintained until the end of the  
procedure (Control, 2.43±3.21; Diabetic, 9.62±4.54 at 28 weeks after STZ injection;  
p<0.001; Fig. 7A, 7B). Although diastolic dysfunction was evident in the diabetic group  
from 4 weeks post-treatment, pulmonary echography signs compatible with HF became  
significant at 20 weeks after STZ injection, highlighting the difference between the  
development of diastolic dysfunction and HF. Stratification of the mice according  
MoLUS≥10.5 or lower at 28 weeks post-injection showed a significant difference in  
several parameters associated with diastolic dysfunction and HF (Table 3).  
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LUS allows to test the efficacy of HF treatments non-invasively 
To determine whether LUS could be used to evaluate the efficacy of a therapeutic  
treatment for HF, a diuretic (furosemide) was administered for 2 weeks to those mice with  
higher MoLUS at 28 weeks after STZ-injection. Treated mice showed a significant  
decrease in the MoLUS score following furosemide administration (before furosemide,  
12.83±2.11; after furosemide, 9.33±2.50; p<0.05 Fig. 7C), suggesting an improvement of  
the HF symptoms. This result indicates that LUS is a useful tool to evaluate therapies  
applied to mouse models of HF.  
 
Discussion 
Mice are the most widely used animals in cardiac research for many reasons. A major  
benefit in using mouse models is the availability of transgenic and knockout strains,  
which enable the identification of gene or protein targets that pave the way for the  
development of new molecular or pharmacological therapies. In addition, recent  
technological advances in echocardiography, MRI and micromanometer conductance  
catheters have greatly streamlined the assessment of cardiac function in rodents.24  
However, there is currently no non-invasive tool to assess HF assessment in mice.  
In this work we report for the first time the use of LUS in mice to identify major  
pulmonary changes associated with HF, similar to the way it is used in human medicine.  
The protocol described here combines pulmonary echography with echocardiography and  
is valid for the study of both HFrEF and HFpEF. Traditionally, lung water content or lung  
weight have represented the gold-standard to recognize lung congestion associated to HF  
in mice. However, this analysis requires prior sacrifice of the animal, thereby precluding  
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the study of HF progression and the response to treatments over time. Considering that  
demonstration of an underlying cardiac disease, which is normally determined by  
echocardiography, is central to the diagnosis of HF, the use of LUS for the assessment of  
HF has substantial advantages. LUS analysis in mice is reliable, reproducible, easy to  
implement, cost-effective and represents virtually no increase in the time needed to  
analyse each animal. Importantly, the results obtained with LUS are in agreement with  
more traditional and invasive indicators of lung congestion, cardiac distress and heart  
failure, including increased water content, cardiac dysfunction and fibrosis.  
LUS is well stablished in medicine for the assessment of pulmonary interstitial fluid in  
patients with HF and suspicion of pulmonary cardiogenic oedema, and has proved higher  
sensitivity and specificity than the clinical exam and chest X-ray.9,25 Considering that  
most HF exacerbations are related to a progressive rise in cardiac filling pressures that  
precipitates pulmonary congestion, resulting in interstitial and alveolar oedema and  
symptomatic decompensation, LUS provides an excellent tool for diagnosis.8,26  
Furthermore, the MOLUS score enables researchers to follow the progression of HF and  
the response to drugs. While we established a cut-off value of 10.5 above which the  
presence of HF is certain, the range of values represents different degrees of HF severity  
that allow to establish differences between conditions beyond a mere binary  
classification. Several studies have also shown that LUS predicts re-hospitalization and  
all-cause mortality in patients admitted with HF. Therefore, it may be used not only to  
diagnose HF but also to monitor the response to different treatments.12,19   
It is important to note that, in medicine, B-lines, pleural irregularities, thickening of  
subpleural septa and low sliding have limited specificity and can be found in the area  
surrounding isolated alveolar consolidations in infectious, infiltrative, sclerosis or  
traumatic lung disease. In addition, it is not always possible to separate extravascular lung  
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water accumulation due to heart failure or due to acute respiratory distress syndrome. 
Differentiation by LUS must include consideration of the clinical context and may be 
supported by other modalities such as echocardiography, which readily detects abnormal 
cardiac or valvular function.26 Similar limitations may be present in mice and, therefore, 
echocardiographic assessment for the detection of systolic or diastolic impairment must 
accompany LUS in order to establish the presence of HF, as shown here.  
In summary, the method presented in this report, combined with existing models of HF 
and genetically modified mice, represents an invaluable resource to follow up HF non-
invasively, investigate new treatments and will allow us to improve our knowledge of 
HF. This is particularly relevant for the study of HFpEF, which accounts for 50% of HF  
cases in humans and for which there are no therapeutic options available. It also opens  
the possibility to study the mechanisms underlying decompensation and the identification  
of new biomarkers that can predict the end stages of HF. Given its potential for  
translational research, we expect that the method described here will pave the way for the  
development of new diagnostic and therapeutic approaches for this highly prevalent  
syndrome.   
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FIGURES LEGENDS 
Figure 1. Lung ultrasound lines profile. Representative schematic (left column) and its 
corresponding real echography (right column) of A, B and Z lines (A, B and C, 
respectively) in mice. A, images belong to a C57BL/6 control mouse, B and C images 
belong to C57Bl/6 diabetic mice.  P, pleura; R, rib; L, liver. Arrows indicate the different 
types of lines.  
 
Figure 2. Representative lung ultrasound (LUS) alterations used to classify 
pulmonary damage and to determine the MoLUS score. (A)  Echography images 
representing typical LUS profiles according to the predominant lines in each image (B) 
Echography images representing typical LUS profiles according to the echography 
background colour (C) Z lines, presented as short perpendicular lines rising from the 
pleura to the lung. (D) Thicker pleura observed in HF. (E) Pleural defects, defined as 
areas where the pleural line is interrupted and irregular (arrow). (F) Pleural effusion, 
visualized as an anechogenic area in the pleural space (arrow).  
 
Figure 3. Cardiac-specific Yme1l knockout mice develop systolic dysfunction and 
dilated cardiomyopathy. (A, B) Echocardiography parameters related to left ventricle 
(LV) contractility (A) and LV dimension (B) in control (Ctl) and cardiac-specific Yme1l 
knockout mice, which develop dilated cardiomyopathy (DCM). (C, D)  Blood serum BNP 
and LV BNP mRNA expression levels were determined in 40 weeks old Ctl and DCM 
mice. (E) Quantification of fibrotic tissue in Ctl and DCM mice. LVEF, left ventricular 
ejection fraction; LVVol,d, left ventricular volume in diastole; w, weeks. Graphs 
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represent mean ±SD. *P<0.05, **P<0.01, ***P< 0.001 compared to the Ctl group and 
♯♯♯P<0.001 compared to previous time points using two-way ANOVA followed by 
Bonferroni (A, B) correction or unpaired t-test (C-E). 
Figure 4. Mice with dilated cardiomyopathy develop pulmonary changes associated 
with HFrEF. (A) LUS representative images of Ctl and DCM mice at 40 weeks of age. 
(B) The mouse lung ultrasound score (MoLUS score) was obtained at 8, 16, 28 and 40 
weeks of age in Ctl and DCM mice. (C) Lung water content was determined in Ctl and 
DCM mice at 28 and 40 weeks of age. MoLUS, mouse lung ultrasound; w, weeks. Graphs 
represent mean ±SD. ***P< 0.001 compared to the Ctl group and ♯♯♯P<0.001 compared 
to previous time points using two-way ANOVA followed by Bonferroni correction.  
Figure 5. The MoLUS score shows good correlation with others parameters related 
to lung congestion and cardiac dysfunction. Control and cardiac-specific Yme1l 
knockout mice, which develop dilated cardiomyopathy (DCM) at 40 weeks of age were 
used. (A) Pearson correlation between the MoLUS score and lung water content. (B-D) 
Correlation between the MoLUS score and echocardiographic parameters related to 
cardiac and lung congestion. (E) Correlation between MoLUS score and left ventricle 
contractility (LV ejection fraction). (F) Correlation between pulmonary artery 
acceleration time and lung water content, used to establish a lung water content cut-off 
value. 
 
Figure 6. Diabetic mice develop early diastolic dysfunction. (A) Blood glucose levels 
obtained in control (Ctl,n=7) and diabetic mice (n=14) at basal, 4, 8, 12, 16, 20, 24 and 
28 weeks after STZ (diabetic) or saline (Ctl) injection. (B, C) Echocardiography 
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parameters related to left ventricle contractility (LVEF, B) and mitral flow pattern , (C) 
were obtained in Ctl (n=7) and diabetic mice (n=14) at baseline and at 4, 12, 20 and 28 
weeks after STZ or saline injection. (D) Blood serum BNP levels were determined at 
different time points after STZ injection by ELISA (Ctl, n=7; diabetic, n=14). (E) BNP 
mRNA expression was analysed by qRT-PCR 28 weeks post-injection in left and right 
ventricle (LV and RV. (F) Collagen distribution was analysed by Masson's trichrome 
staining in Ctl and diabetic mice and quantified as percentage of total myocardial area. 
LVEF, left ventricular ejection fraction; Graphs represent mean ±SD. *P<0.05, 
**P<0.01, ***P< 0.001 compared to the control group and ♯♯P<0.01, ♯♯♯P<0.001 
compared to previous time points using two-way ANOVA followed by Bonferroni 
correction (A, B, C, D) or a unpaired Student t-test (E, F). 
Figure 7. Diabetic mice develop pulmonary changes associated with HFpEF. (A) 
Representative images of LUS in Ctl and diabetic mice 28 weeks after injection. (B) The 
MoLUS score was determined at baseline and at 4, 12, 20 and 28 weeks after STZ or 
saline injection. (C) Diabetic mice with the highest MoLUS score (n=6) were treated with 
the diuretic furosemide for 7 days and analysed again by LUS. MoLUS, mouse lung 
ultrasound score. Graphs represent mean ±SD. *P<0.05, ***P< 0.001 compared to the 
control group and ♯♯♯P<0.001 compared to previous time points using two-way ANOVA 
followed by Bonferroni correction (B) or a paired Student t-test (C). 
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TABLES 
Parameter                MoLUS score 
Sliding 
 Normal 0 
 Low 1 
 Absent 2 
Profile 
 A 0 
 AB 2 
 B 4 
Echo colour 
 Black 0 
 Black and White 2 
 White 4 
Z lines 
 Absent 0 
 Present 1 
Pleural thickness 
 ≤ 0.3 mm 0 
 > 0.3 mm 3 
Pleural defects 
 Absent 0 
 Present 3 
Pleural effusion  
 Absent 0 
 Moderate 2 
 Severe 4 
Table 1. Score developed to assess pulmonary changes in mice by lung echography. 
The table summarizes all the parameters used to diagnose heart failure in mice and their 
respective possible scores. The analysis of each parameter is described in Methods. LUS, 
Lung ultrasound; MoLUS, Mouse Lung Ultrasound. 
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  MoLUS score in HFrEF 
  < 10.5 (n=16) >10.5 (n= 7) p-value 
LVVol,d (µl) 78.53±20.99 151.25±22.03 0.003 
LAID(mm) 2.29±0.23 3.36±0.70 <0.001 
LVEF (%) 46.26±18.57 12.26±5.17 <0.001 
PA mean vel (mm/sec) -315±102 -197±31 0.006 
PA AccT (mm/sec2) 16.78±3.05 12.78±3.44 0.008 
PA VTI 13.01±7.03 9.45±1.99 0.002 
Ao CO 17.12±5.54 13.88±9.73 0.004 
Lung water content 0.11±0.01 0.17±0.02 <0.001 
Table 2. Cardiovascular and pulmonary differences among groups established 
based on the MoLUS score cut-off of 10.5 in 40 weeks-old mice with dilated 
cardiomyopathy. LVVol,d, left ventricle end-diastolic volume; LVID, left atrial internal 
diameter; LVEF, left ventricle ejection fraction; PA mean vel; pulmonary artery mean 
velocity; PA AccT, pulmonary artery acceleration time; PA VTI; pulmonary artery 
velocity time integral; Ao CO, cardiac output from aortic flow; ns, not significant. 
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  MoLUS score HFpEF 
  < 10.5 (n=14) >10.5 (n= 6) p-value 
LVVol,d (µl) 59.14±13.11 45.58±12.94 0.03 
LAID(mm) 2.26±0.26 2.20±0.21 ns 
LVEF (%) 58.08±11.48 58.78±4.16 ns 
PA mean vel (mm/sec) -349±42 -285±57 0.005 
PA AccT (mm/sec2) 17.66±3.32 15.14±2.07 0.05 
PA VTI 23.06±3.49 21.47±3.90 ns 
Ao CO 16.39±5.72 13.51±6.79 ns 
IVRT 20.13±4.35 28.559.70 0.006 
Lung water content 0.11±0.01 0.17±0.02 <0.001 
Table 3. Cardiovascular and pulmonary differences among groups established 
based on the MoLUS score cut-off of 10.5 in diabetic mice 28 weeks after STZ-
injection. LVVol,d, left ventricle end-diastolic volume; LVID, left atrial internal 
diameter; LVEF, left ventricle ejection fraction; PA mean vel; pulmonary artery mean 
velocity; PA AccT, pulmonary artery acceleration time; PA VTI; pulmonary artery 
velocity time integral; Ao CO, cardiac output from aortic flow. IVRT, isovolumetric 
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Supplemental methods 1 
Lung water content 2 
The difference between the lung wet and dry weights was used as an index of pulmonary 3 
congestion. Lungs were extracted and weighed immediately (wet weight). Lungs were then 4 
dried at 65ºC in an oven for 5 days and weighed again (dry weight). 5 
 6 
Blood mouse brain natriuretic peptide analysis 7 
To determine the blood brain natriuretic peptide (BNP) serum levels, cardiac blood samples 8 
(100 µL) were collected from the facial vein in the diabetic model and directly from the left 9 
ventricle (immediately after euthanasia with CO2) in the DCM model. Serum BNP was 10 
analysed using an immunoassay kit specific for mice (Raybio ELISA BNP kit; RayBiotech Inc., 11 
USA). 12 
 13 
Cardiac and lung quantitative real-time reverse-transcribed polymerase chain reaction 14 
(qRT-PCR) 15 
A portion of right and left ventricle, cardiac septum and lung tissue was snap-frozen in liquid 16 
nitrogen. Total RNA was extracted using the RNAeasy kit (Qiagen). The cDNA was 17 
synthesized (iScript cDNA synthesis kit, Bio-Rad, Hercules, CA, USA) and quantitative real-18 
time reverse-transcribed polymerase chain reaction (qRT–PCR) was performed using SYBR 19 
green as previously described 1 (Applied Biosystems). The following primers were used: BNP 20 
(forward: 5'GCCAGTCTCCAGAGCAATTC3'; reverse: 5'-TCTTTTGTGAGGCCTTGGTC-21 
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3'), Lox (forward: 5´-GCTGCGGA AGAAAACTGC-3´; reverse: 5'´-1 
CCTTGGTTCTTCACTCTTTGC-3'), CD45 (forward:5'- CCCCACCCTTACATCAGCTT-3'; 2 
reverse: 5'-CTGGGATGCACACACACACT-3') and Gapdh (forward: 5'-3 
CTGCACCACCAACTGCTTAG-3'; reverse: 5'-AGATCCACGACGGACACATT-3'). Gene 4 
expression was normalized to Gapdh or total mRNA .  5 
 6 
Histology and immunohistochemistry 7 
Cardiac and lung samples were fixed in 4% paraformaldehyde during 24 h or 48 h, respectively, 8 
washed, dehydrated, included in paraffin and cut into 4 µm thick sections. Cardiac fibrosis was 9 
analysed by using Masson's trichrome staining and quantified in 20x fields using Image J (NH, 10 
USA) as previously described.2 Pulmonary specimens were stained with Picrosirius red and 11 
collagen was visualised by microscopy under bright and polarized light. Macrophages were 12 
detected by immunohistochemistry using the F4/80 antibody.  13 
 14 
 15 
  16 
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Supplemental Tables 1 
MoLUS score, first evaluation MoLUS score, second evaluation 
Image Obv1 Obv2 Obv3 Obv4 Obv5 Obv6  Obv1 Obv2 Obv3 Obv4 Obv5 Obv6 
1 15 13 14 12 17 17  19 15 10 5 17 14 
2 3 1 0 1 1 1  7 1 3 5 1 1 
3 13 13 3 0 8 6  8 7 3 0 7 1 
4 2 0 0 0 0 0  5 2 1 0 1 1 
5 11 3 2 0 6 1  12 3 3 0 0 0 
6 2 0 2 0 2 0  1 2 1 0 0 1 
7 1 0 0 0 2 1  2 0 1 0 1 1 
8 17 18 11 19 20 9  17 18 13 15 19 9 
9 14 4 5 2 7 4  15 4 4 0 6 4 
10 16 16 12 19 13 13  17 19 13 17 15 15 
11 9 4 3 0 1 1  8 2 2 0 1 1 
12 6 10 1 7 5 8  6 10 6 6 9 8 
13 13 11 9 12 9 10  13 11 10 7 11 10 
14 2 4 1 0 1 0  3 4 0 0 0 0 
15 12 14 9 15 11 11  12 14 11 15 11 13 
16 0 2 1 0 3 0  3 2 0 0 1 0 
17 12 9 9 17 11 8  13 14 11 14 9 8 
18 4 6 3 4 1 2  6 5 3 0 4 1 
19 1 2 1 1 0 0  4 2 0 0 1 0 
20 3 5 1 2 1 0  3 2 0 2 1 0 
21 1 1 0 1 0 1  3 2 2 2 4 0 
22 0 0 1 0 0 0  0 2 0 0 0 0 
23 13 18 13 16 14 15  14 15 14 10 14 15 
24 1 3 3 0 0 1  1 3 0 0 0 0 
25 1 2 1 0 0 1  4 0 2 0 1 4 
26 11 12 9 17 10 8  15 12 7 17 11 10 
27 15 8 11 16 9 13  15 6 10 14 10 15 
28 13 9 10 17 9 8  13 16 10 11 8 8 
29 11 9 8 7 9 9  12 9 7 11 7 9 
30 4 1 0 0 1 0  5 4 0 1 2 0 
31 6 6 4 2 1 1  9 6 2 1 6 4 
32 2 2 2 0 4 0  5 2 1 1 4 0 
Table S1. MoLUS score assigned to 32 pulmonary echographies of diverse severity by 6 2 
independent observers. The left columns show the 32 images scored on the first time and the second 3 
column shows the score assigned by the same observers in a second evaluation, with the images in 4 
different order and without being told they were the same images. Obv, Observer. 5 
  6 
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Age (weeks) 
  8 16 28 40 
 LAX 2D LVEF (%) 











LAX 2D LVVol,s (µL) 











SAX 2D LVFAC (%) 











APICAL 2D TAPSE (mm) 












Ctl  8 9 9 9 
DCM  8 8 9 9 
Table S2. Echocardiographic parameters related to systolic function, myocardial contractility and 1 
infarct size in a mouse model of DCM. LAX, long axis; SAX, short axis; 2D, bidimensional mode; 2 
LVEF, left ventricular ejection fraction; LVVol,s, left ventricular volume in systole; LVFAC, left 3 
ventricular fractional area change; TAPSE, tricuspid anterior systolic excursion; Ctl, control group; 4 
DCM, dilated cardiomyopathy group. Data are presented as mean ±SD. *P<0.05, **P<0.01, ***P< 5 
0.001 compared to the control group and ♯P<0.05, ♯♯P<0.01, ♯♯♯P<0.001 compared to baseline time point 6 
using a two-way ANOVA with Bonferroni correction. 7 
 8 
  9 
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Age (weeks) 
  8 16 28 40 
LAX 2D LVVol,d (µL) 











LAX 2D LAID (mm) 











PA accT (mm/sec2) 











PA Mean Vel (mm/sec) 























LW/TLength ratio (mg/cm) 











Lung water content (mg) 
Ctl    91.9±8.2 102.6±013.8 
DCM 





HW/TLength ratio (mg/cm) 
Ctl  - - 6.91±0.78 7.38±0.70 
DCM 






Ctl  8 9 9 9 
DCM  8 8 9 9 
Table S3. Echocardiographic parameters related to cardiac dimensions, pulmonary hypertension 1 
and pulmonary pattern in a mouse model of DCM. LAX, long axis; 2D, bidimensional mode; 2 
LVVol,d, left ventricular volume in diastole; LAID, left atrial internal diameter; PA AccT, pulmonary 3 
artery acceleration time; PA Mean Vel, pulmonary artery mean velocity; MoLUS, mouse lung 4 
ultrasound score; LW, lung weight; TLength, tibial length; Ctl, control group; DCM, dilated 5 
cardiomyopathy group. Data are presented as mean ±SD. *P<0.05, **P<0.01, ***P< 0.001 compared 6 
to the control group and ♯P<0.05, ♯♯P<0.01, ♯♯♯P<0.001 compared to baseline time point using a two-7 
way ANOVA with Bonferroni correction or unpaired t-test. 8 
 9 
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Time (weeks after STZ injection) 
 Basal 4 8 12 16 20 24 28 
LAX 2D LVEF (%) 



















LAX 2D LVVol.s (µL) 



















SAX 2D LVFAC (%) 
Ctl 48±5 47±6 47±5 47±7 47±6 48±6 54±6 46±7 
Diabetic 48±10 54±6 55±9 52±9 550±10 52±7 49±7 51±8 
APICAL 2D TAPSE (mm) 
Ctl 1.06±0.13 0.90±0.2 0.85±0.13 0.94±0.23 0.86±0.12 0.86±0.13 0.95±0.11 0.96±0.16 
Diabetic 0.94±0.11 0.86±0.22 0.87±0.21 0.93±0.14 0.89±0.20 0.78±0.13 0.85±0.17 0.89±0.23 
Body weight (g) 




















Ctl 7 7 7 7 7 7 7 7 
Diabetic 14 14 14 14 14 14 14 14 
Table S4. Echocardiographic parameters related to systolic function and body weight in a mouse model of diabetic cardiomyopathy. LAX, long axis. 
SAX, short axis; 2D, bidimensional mode; LVEF, left ventricular ejection fraction; LVVol.s, left ventricular volume in systole; LVFAC, left ventricular 
fractional area change; TAPSE, tricuspid anterior systolic excursion; TAPSE; Ctl, control group; Diabetic, diabetic group. Data are presented as mean 
±SD. *P<0.05, **P<0.01, ***P< 0.001 compared to the control group and ♯P<0.05, ♯♯P<0.01, ♯♯♯P<0.001 compared to baseline time point using a two-way 
ANOVA with Bonferroni correction. 
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 Time (weeks after STZ injection) 
 Basal 4 8 12 16 20 24 28 
E/A ratio 
Ctl 2.03±0.21 2.26±0.64 2.30±0.66 1.85±0.56 1.68±0.22 1.74±0.61 1.56±0.41 1.57±0.28 
Diabetic 1.81±0.42 1.5±0.36 2.19±0.89 1.37±0.26 1.29±0.40 1.25±0.23 1.42±0.24 2.27±2.58 
Abnormal E/A (% mice) 



















 IVRT (ms) 




















Ctl 7 7 7 7 7 7 7 7 
Diabetic 14 14 14 14 14 14 14 14 
Table S5. Echocardiography parameters related to diastolic function in a mouse model of diabetic cardiomyopathy. E, early mitral wave; A, active mitral 
wave; IRVT, isovolumetric relaxation time; Ctl, control group; Diabetic, diabetic group. Data are presented as mean ±SD. *P< 0.05, **P< 0.01, *** P < 0.001 
compared to baseline and ♯P<0.05, ♯♯P<0.01, ♯♯♯P<0.001 compared to the control group using a two-way ANOVA with Bonferroni correction or a Chi-squared 
Test in abnormal E/A ratio. 
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Time (weeks after STZ injection) 
  Basal 4 8 12 16 20 24 28 
LAX 2D LVVol.d (µL) 



















LAX 2D LAID (mm) 
Ctl  2.29±0.25 2.30±0.35 2.33±0.14 2.33±0.34 2.24±0.33 2.28±0.19 2.11±0.24 2.32±0.29 
Diabetic  2.41±0.23 2.44±0.23 2.48±0.23 2.25±0.26 2.39±0.19 2.23±0.47 2.34±0.19 2.17±0.19 
PA accT (mm/sec2) 



















PA Mean Vel (mm/sec) 
Ctl  -367±37 -385±43 -392±65 -432±78 -389±40 -413±74 -377±44 -357±41 
Diabetic  -365±47 -371±68 -395±72 -389±54 -365±49 -342±46 -333±42 -316±57 
MoLUS score 



















Diuretic effect in HF  
MoLUS  before furosemide - - - - - - - 12.83±2.71 

















         Ctl 7 7 7 7 7 7 7 7 
        Diabetic 14 14 14 14 14 14 14 14 
Table S6. Echocardiographic parameters related to cardiac dimensions. pulmonary hypertension and pulmonary pattern in a mouse model of diabetic 
cardiomyopathy. SAX, short axis; LAX, long axis; 2D, bidimensional mode; LVVol.d, left ventricular volume in diastole; LAID, left atrial internal diameter; 
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PA AccT, pulmonary artery acceleration time; PA Mean Vel, pulmonary artery mean velocity; MoLUS, mouse lung ultrasound score; Ctl, control group; 
Diabetic, diabetic group. Data are presented as mean ±SD. *P<0.05, **P<0.01, ***P< 0.001 compared to the control group and ♯P<0.05. ♯♯P<0.01, ♯♯♯P<0.001 
compared to baseline time point using a two-way ANOVA with Bonferroni correction or a t-test for repeated measures to compare mice receiving furosemide 
before and after treatment.  
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Supplemental Figure Legends 
 
Supplemental Figures 
Figure S1. Lung ultrasound images and their corresponding MoLUS score as 
examples of score assessment. Representative images (A) and their individual MoLUS 
score (B) are shown. * Parameters should be ideally assessed in live images (i.e. not still). 
 
 
Figure S2. Assessment of lung fibrosis and inflammation in the DCM mouse model. 
(A) Representative 4 µm lung sections stained with Picrosirius red and visualized under 
bright light (left panels) or polarized light (right panel) to highlight collagen deposition in 
control (Ctl) and cardiac-specific Yme1l knockout mice (DCM). Black arrows indicate the 
vessel. White arrows indicate collagen deposition surrounding the lung vessel. (B) The 
presence of macrophages in the lung of Ctl and DCM mice at 40 weeks was determined by 
immunohistochemistry using F4/80. Red arrows indicate macrophages, which are hardly 
visualized in both mouse groups. (C) Lung mRNA expression of lysyl oxidase and CD45 
was analysed by qRT-PCR in Ctl and DCM mice at 40 weeks old. Br. bronchus; Ve. vessel; 
Pol. polarized light. Lox. Lysyl oxidase. Graphs represent mean ±SD. **P<0.01 compared 
to the control group, unpaired t-test. Bar. 100 µm. 
 
Figure S3. Assessment of lung fibrosis in the diabetic mouse model. (A) Representative 
4 µm lung sections stained with Picrosirius red and visualized under bright (left panels) or 
polarized light (right panel) to highlight collagen deposition in mice 28 weeks after 
receiving saline (Ctl) or STZ (Diabetic) injections. Black arrows indicate a vessel. White 
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arrows indicate collagen deposition surrounding the lung vessel. (B) Macrophages were 
identified by immunohistochemistry using F4/80 in Ctl and diabetic mice 28 weeks after 
diabetes induction. Red arrows indicate macrophages. which are hardly visualized in both 
samples. (C, D) Lung mRNA expression of lysyl oxidase (Lox, C) and CD45 (D) was 
analysed by qRT-PCR in Ctl and diabetic mice 28 weeks after saline or STZ injection. Br. 
bronchus; Ve. vessel; Pol. polarized light; Lox. Lysyl oxidase. Graphs represent mean ±SD. 




Video S1. Representative lung ultrasound (LUS) alterations used to classify pulmonary 
damage and to determine the MoLUS score. Echography images representing typical LUS 
profiles are shown. 
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